Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has been given a consensus rating of “Moderate Buy” by the eleven research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $131.30.

Several analysts have weighed in on ORKA shares. Guggenheim set a $200.00 target price on shares of Oruka Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 27th. Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Wall Street Zen raised shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 16th. Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a research report on Monday, April 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st.

Oruka Therapeutics Stock Up 4.5%

NASDAQ ORKA opened at $66.93 on Friday. The firm has a market cap of $4.04 billion, a PE ratio of -34.50 and a beta of -0.26. The company has a 50 day moving average price of $62.25 and a 200 day moving average price of $43.22. Oruka Therapeutics has a 52 week low of $10.77 and a 52 week high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.04. On average, equities research analysts anticipate that Oruka Therapeutics will post -2.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $61.85, for a total value of $432,950.00. Following the sale, the insider directly owned 33,377 shares of the company’s stock, valued at $2,064,367.45. This represents a 17.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the sale, the chief executive officer directly owned 927,309 shares in the company, valued at $38,297,861.70. This trade represents a 0.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 139,055 shares of company stock valued at $8,095,785 over the last quarter. Insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Avidity Partners Management LP boosted its holdings in Oruka Therapeutics by 15.1% during the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after buying an additional 100,000 shares in the last quarter. Glenmede Trust Co. NA raised its position in Oruka Therapeutics by 11.7% during the first quarter. Glenmede Trust Co. NA now owns 21,772 shares of the company’s stock worth $1,068,000 after acquiring an additional 2,287 shares during the period. Remedium Capital Partners LLC raised its position in Oruka Therapeutics by 0.9% during the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock worth $76,796,000 after acquiring an additional 13,247 shares during the period. Royal Bank of Canada raised its position in Oruka Therapeutics by 178.5% during the first quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock worth $155,000 after acquiring an additional 2,033 shares during the period. Finally, Rock Springs Capital Management LP acquired a new position in Oruka Therapeutics during the first quarter worth $202,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.